A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
10/2001
10/17/2001	EP1144443A2 Human membrane transport proteins
10/17/2001	EP1144435A2 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144425A1 Derivatives of monosaccharides as cell adhesion inhibitors
10/17/2001	EP1144411A1 Antihistaminic spiro compounds
10/17/2001	EP1144402A2 Substituted oximes and hydrazones as neurokinin antagonists
10/17/2001	EP1144397A2 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
10/17/2001	EP1144396A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
10/17/2001	EP1144394A1 1-heterocycle substituted diarylamines
10/17/2001	EP1144393A2 Heterocyclic derivatives and their use as integrin inhibitor
10/17/2001	EP1144390A2 Kinase inhibitors
10/17/2001	EP1144388A1 Acyl derivatives which treat vla-4 related disorders
10/17/2001	EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
10/17/2001	EP1144385A1 Benzoheterocycles and their use as mek inhibitors
10/17/2001	EP1144384A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144372A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
10/17/2001	EP1144371A1 Benzenesulphonamide derivatives and their use as mek inhibitors
10/17/2001	EP1144370A2 Thyroid receptor ligands
10/17/2001	EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/17/2001	EP1144365A2 Inhibitors of alpha-4 beta-1 mediated cell adhesion
10/17/2001	EP1144364A2 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144362A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
10/17/2001	EP1144348A2 Lta 4? hydrolase inhibitors
10/17/2001	EP1144305A1 NOVEL sPLA 2 INHIBITORS
10/17/2001	EP1144008A1 Modulation of systemic memory t cell trafficking
10/17/2001	EP1143995A1 Anti-dandruff composition comprising an antifungal polypeptide
10/17/2001	EP1143984A1 Egg anti-inflammatory composition and method of treating and preventing inflammation
10/17/2001	EP1143983A1 Spray delivery of cells
10/17/2001	EP1143965A1 Carbocyclic potassium channel inhibitors
10/17/2001	EP1143961A2 Regulators of the ptc or smoothened pathway, compositions and uses related thereto
10/17/2001	EP1143960A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
10/17/2001	EP1143956A2 Compositions and methods for the treatment of anorectal disorders
10/17/2001	EP1143954A2 Use of nicotonic acid derivatives for the treatment of dna damage in skin cells
10/17/2001	EP1143949A2 19-nor-vitamin d3 compounds with calcemic activity
10/17/2001	EP1143947A2 Use of estrogen compounds for prevention and treatment of ischemic damage
10/17/2001	EP1143946A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
10/17/2001	EP1143944A2 Use of arylalkanoylpyridazines
10/17/2001	EP1143943A2 P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
10/17/2001	EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers
10/17/2001	EP1143927A2 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants
10/17/2001	EP1143925A1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids
10/17/2001	EP1143920A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system
10/17/2001	EP1143916A2 Topical compositions comprising protected functional thiols
10/17/2001	EP1001955B1 1,2,4-triazolo 4,3-b]pyrido 3,2-d]pyridazine derivatives and pharmaceutical compositions containing them
10/17/2001	EP0808103A4 Protein hydroxylation inhibitors for fibroproliferative disorders
10/17/2001	CN1318059A Isoquinolines as urokinase inhibitors
10/17/2001	CN1318056A Pyridinum derivatives for management of aging-related and diabetic vascular complications, process for their prepn. and therepeutic uses thereof
10/17/2001	CN1318054A Novel compounds
10/17/2001	CN1317326A Detoxicating compound oral liquid and its preparing process
10/17/2001	CN1317322A Liquid medicine 'Yanyouye'
10/17/2001	CN1317308A Skin-protecting cream suitable for face
10/17/2001	CN1073154C Superoxide dismutase-4
10/17/2001	CN1072944C Externally used Chinese medicine liquid prepared from plants, method and use thereof
10/17/2001	CN1072928C Mild antimicrobial liquid cleaning agent
10/16/2001	US6303789 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
10/16/2001	US6303656 For therapy and/or prophylaxis of human skin, mucous membranes and/or keratin fibers, in particular for moisturizing the skin and for treatment of dry skin
10/16/2001	US6303653 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
10/16/2001	US6303641 Cyanoamidines as cell proliferation inhibitors
10/16/2001	US6303637 For therapy of autoimmune disease, prophylaxis of resistance to transplantation or transplantation rejection of organs or tissues; suppressing immune system
10/16/2001	US6303636 Arylsulfonylamino hydroxamic acid derivatives
10/16/2001	US6303600 Substituted azabicyclic compounds
10/16/2001	US6303576 Contacting cell with modulating agent that comprises internalization moiety and compound having amino acid sequencel peptide analogue or peptidomimetic of compound which retains ablity to inhibit beta-catenin mediated response
10/16/2001	US6303126 Treatment of fibrosis by HGF
10/16/2001	CA2087969C Protease resistant pdgf and methods of use
10/16/2001	CA2028528C Hydrogel wound dressing product
10/16/2001	CA2015470C Fluorinated arachidonic acid derivatives
10/13/2001	CA2344182A1 Therapeutic agent for dermatitis
10/12/2001	CA2318665A1 Method of treating onychomycosis
10/11/2001	WO2001075108A1 Human ion channel protein and polynucleotides encoding the same
10/11/2001	WO2001075078A1 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
10/11/2001	WO2001075074A1 Novel proteins
10/11/2001	WO2001074903A2 CD20/IgE-RECEPTOR LIKE MOLECULES AND USES THEREOF
10/11/2001	WO2001074896A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	WO2001074841A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
10/11/2001	WO2001074835A1 O-glucosylated benzamide sglt2 inhibitors and method
10/11/2001	WO2001074834A1 O-aryl glucoside sglt2 inhibitors and method
10/11/2001	WO2001074812A1 Novel benzosultam oxazolidinone antibacterial agents
10/11/2001	WO2001074811A2 Substituted 1,3-thiazole compounds, their production and use
10/11/2001	WO2001074780A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001	WO2001074775A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/11/2001	WO2001074766A1 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses
10/11/2001	WO2001074765A1 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
10/11/2001	WO2001074506A1 Extrusion die
10/11/2001	WO2001074413A1 Medical devices suitable for gene therapy regimens
10/11/2001	WO2001074369A1 Divided dose therapies with vascular damaging activity
10/11/2001	WO2001074360A1 Therapeutic combinations of antihypertensive and antiangiogenic agents
10/11/2001	WO2001074359A1 Sigma receptor ligands and their medical uses
10/11/2001	WO2001074344A2 Small organic molecule regulators of cell proliferation
10/11/2001	WO2001074327A1 Composition for improving skin lipid barrier function
10/11/2001	WO2001074326A1 Agents improving skin barrier function
10/11/2001	WO2001074317A1 Methods of modulating hair growth
10/11/2001	WO2001074315A2 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
10/11/2001	WO2001074314A2 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
10/11/2001	WO2001074313A2 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins
10/11/2001	WO2001074307A2 Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins
10/11/2001	WO2001074299A2 Compositions and methods for inhibition of cancer invasion and angiogenesis
10/11/2001	WO2001074165A1 Chitosan formulation with azelaic acid and other actives for the treatment of acne
10/11/2001	WO2001074164A1 Methods of modulating hair growth
10/11/2001	WO2001034572A3 Carboxamide-substituted benzimidazol derivatives, method for the production thereof and their use as tryptase inhibitors
10/11/2001	WO2001027119A3 Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines
10/11/2001	WO2001024763A3 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents

1 ... 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 ... 1065